Shots:
The company launches Alymsys, a biosimilar referencing Avastin to provide additional access and options to patients and physicians for affordable oncology treatments
Alymsys is a vascular endothelial growth factor inhibitor used in oncology that was developed by mAbxience with an experience in the development, manufacture, and commercialization of biopharmaceuticals
Additionally, the company also seeks to increase the number of molecules in its biosimilar portfolio and has a growing line of branded pharmaceutical products with a primary focus on endocrine and central nervous system disorders
Ref: Businesswire | Image: Amneal
